Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive [clinicaltrials:NCT00093093]

Bio2RDF uri

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive [clinicaltrials:NCT00093093]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00093093

Bio2RDF identifier

NCT00093093

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00093093

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00093093

acronym [clinicaltrials_vocabulary:acronym]

VISER2

http://www.w3.org/2001/XMLSchema#string

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... er before received treatment.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Study of Viramidine to Ribavir ...... itis C Who Are Treatment Naive

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period. [clinicaltrials_resource:4d234cdb5f451de9dd5f13d59b4bf9a1]

- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period. [clinicaltrials_resource:51d4f8e212f6ebfcd44daeb82285595a]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period. [clinicaltrials_resource:3642239b1c593f7fc543e262a7253386]

- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period. [clinicaltrials_resource:48e004423508938b89cdbab61386ff64]

- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period. [clinicaltrials_resource:b04f41414310c9db711fa49663e685d9]

- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period. [clinicaltrials_resource:c81eb01edeedb09b85d55785a0da63b6]

completion date [clinicaltrials_vocabulary:completion-date]

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Compare the efficacy an ...... ith chronic hepatitis C (CHC)

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00093093 [clinicaltrials_resource:55b49d3a1da19d14e8d0cf4463e64d19]

enrollment [clinicaltrials_vocabulary:enrollment]

900

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2004-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

pegylated interferon alfa-2a [clinicaltrials_resource:17405069b0ea46b4befb09f24ef263a0]

Ribavirin [clinicaltrials_resource:86c64449f4fcd44a9e1a84acf7d388f8]

Viramidine [clinicaltrials_resource:faf049c990f3e48eac976bd321e92d68]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Interferon-alpha [clinicaltrials_resource:411321421382b10c54a06fd59fb19d27]

Interferons [clinicaltrials_resource:ac14a704eab186e8681cb6c21160bdb2]

Ribavirin [clinicaltrials_resource:c260972ef8fb801d491757e72eeceb79]

Peginterferon alfa-2a [clinicaltrials_resource:ea2504b16a94f43e40b345f0551d81c0]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Hepatitis C

http://www.w3.org/2001/XMLSchema#string

Pegylated interferon alfa-2a

http://www.w3.org/2001/XMLSchema#string

Ribavirin

http://www.w3.org/2001/XMLSchema#string

Valeant

http://www.w3.org/2001/XMLSchema#string

Viramidine

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2012-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Valeant Pharmaceuticals International, Inc. [clinicaltrials_resource:4967221387cfa17d8c3bac341a227d9f]

location [clinicaltrials_vocabulary:location]

University of Arizona [clinicaltrials_resource:81d974c322ecdc4e035a21fea98cbd56]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00093093

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

Randomized, Double-Blind, Mult ...... ients With Chronic Hepatitis C

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

RNA003142-302

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Ralph T. Doyle [clinicaltrials_resource:5bc3f98a64a702b57e9129b2c733a011]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:77fa11db9aea1d8cd0ff35db5bc538f2]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Valeant Pharmaceuticals International, Inc. [clinicaltrials_resource:4967221387cfa17d8c3bac341a227d9f]

start date [clinicaltrials_vocabulary:start-date]

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00093093 study design [clinicaltrials_resource:a3a50a4ade5013408b9595744f5408e9]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00093093

verification date [clinicaltrials_vocabulary:verification-date]

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00093093

http://www.w3.org/2001/XMLSchema#string

title

Study of Viramidine to Ribavir ...... itis C Who Are Treatment Naive

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Study of Viramidine to Ribavir ...... e [clinicaltrials:NCT00093093]

@en